BioSyntech, Inc.
BSYIOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$229033
P/E Ratio—
52W High$0.00001
52W Low$0.000001
BioSyntech, Inc.（BSYI）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · BSYI · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2009-03 | 2008-03 | 2007-03 | 2006-03 | 2005-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.04M | $0.27M | $0.24M | $0.06M | $0.18M |
| Cost of Revenue | $0.02M | $0.10M | $0.47M | $0.02M | $0.08M |
| Gross Profit | $0.02M | $0.17M | $0.15M | $0.04M | $0.10M |
| Gross Margin %(computed) | 60.82% | 62.81% | 63.09% | 65.20% | 55.15% |
| Operating Expenses | |||||
| R&D Expenses | $5.80M | $6.02M | $4.96M | $3.20M | $1.85M |
| G&A Expenses | $3.01M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $11.05M | $9.37M | $7.73M | $6.41M | $4.88M |
| Operating Income | ($11.03M) | ($9.20M) | ($7.30M) | ($6.37M) | ($4.78M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.14M | $0.32M | $0.00M | $0.07M | $0.03M |
| Interest Expense | $0.26M | $0.38M | $0.00M | $0.61M | $0.42M |
| Income Before Tax | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($12.94M) | ($9.27M) | ($8.11M) | ($6.86M) | ($5.14M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.13 | $-0.10 | $-0.09 | $-0.17 | $-0.14 |
| Wtd Avg Shares | 95.90M | 95.49M | 94.20M | 40.94M | 36.20M |
| EBITDA | ($10.62M) | ($8.76M) | ($7.89M) | ($5.81M) | ($4.26M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · CAD · M
深入了解BioSyntech, Inc.
关于BioSyntech, Inc.（BSYI）损益表
BioSyntech, Inc.（BSYI）损益表数据来源于SEC Form 10-K及10-Q申报文件。2009财年，BSYI实现营收$0.00B，毛利润$0.00B（毛利率60.82%），净利润($0.01B)（净利率-31739.11%）。
常见问题
BSYI · 4 问BioSyntech, Inc.（BSYI）2009财年营收为$0.00B，同比down85.1%。
BSYI revenueBSYI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09